Anastrozole and SLU-PP-332 Interaction
Anastrozole and SLU-PP-332 have a potentially harmful interaction with 53% confidence. Both Anastrozole and SLU-PP-332 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. These compounds primarily affect different organ systems.
Compound Profiles
Anastrozole
Aromatase Inhibitor | Estrogen Management
Anastrozole competitively binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), reversibly inhibiting its catalytic activity. Aromatase is responsible for the final step in estrogen biosynthesis, converting testosterone to estradiol and androstenedione to estrone in peripheral tissues including adipose, muscle, liver, and brain.
View full profileSLU-PP-332
Synthetic Pan-ERR Agonist | Exercise Mimetic & Metabolic Modulator
Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density to 1.
View full profileCombined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take Anastrozole with SLU-PP-332?
Combining Anastrozole with SLU-PP-332 is not recommended. Both Anastrozole and SLU-PP-332 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Is Anastrozole and SLU-PP-332 safe together?
This combination carries significant risk. Both Anastrozole and SLU-PP-332 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.
What are the interactions between Anastrozole and SLU-PP-332?
Both Anastrozole and SLU-PP-332 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 53% confidence and is inferred from pharmacological mechanism analysis.
How should I time Anastrozole and SLU-PP-332?
Anastrozole has a half-life of ~40-50 hours and SLU-PP-332 has a half-life of Under investigation (no human PK data). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.